Biomedical technology company Biomerica Inc (Nasdaq: BMRA) announced on Wednesday that it has achieved In Vitro Diagnostic Regulation (IVDR) certification in the European Union for its food intolerance tests targeting Crohn's Disease and Ulcerative Colitis.

This milestone allows the company to sell its products in the EU while adhering to stringent safety and quality standards.

The certified products address the growing demand for non-invasive, personalised therapies for these chronic inflammatory bowel diseases which affect millions globally. Biomerica's food intolerance tests use proprietary technology to identify dietary triggers that may exacerbate inflammation in affected patients.

With this achievement, Biomerica is poised to expand its footprint in the European in vitro diagnostic market. IVDR certification also facilitates easier market access in other international markets that recognise EU standards.